ANTI-ULCER EFFECTS OF 4’-(2-CARBOXYETYL) PHENYL TRANS-4-AMINOMETHYL CYCLOHEXANECARBOXYLATE HYDROCHLORIDE (CETRAXATE) ON VARIOUS EXPERIMENTAL GASTRIC ULCERS IN RATS

Open Access
Publisher Website
Google Scholar
Abstract
Anti-ulcer effects of cetraxate, a new compound possessing anti-plasmin, anti-casein and anti-trypsin actions were investigated by using experimental gastric ulcer models in rats. Cetraxate, 300 mg/kg orally showed significant inhibitory effects of 65.3%, 70.0%, 30.2% and 67.1% against acute types of ulcers produced by aspirin, phenylbutazone, indomethacin and pyloric ligature (Shay''s ulcer), respectively. These effects were greater than those obtained by gefarnate and aluminum sucrose sulfate and may be mainly attributed to the protecting action of this drug on gastric mucosa. Cetraxate further revealed inhibitory effects on chronic types of ulcers produced by acetic acid, clamping and clamping-cortisone. In acetic acid ulcer in particular, cetraxate had a dose-dependent inhibitory effect at doses over 50 mg/kg. Of test drugs including L-glutamine and methylmethionine sulfonium chloride, cetraxate showed the most remarkable inhibitory effect on .beta.-glucuronidase activity in ulcer tissue of these 3 types of ulcers. Detraxate may prevent the connective tissue in the ulcer location from decomposition due to lysosomal enzymes such as .beta.-glucuronidase, thereby accelerating the recovery from ulcer.